Dr Collen will remain chairman of ThromboGenics’s board of directors. This new structure is said to ensure the continuity of ThromboGenics’s senior management.
Prior to joining ThromboGenics, Dr De Haes was head of the global insulin infusion business at Roche Diagnostics in Bern, Switzerland.
Dr Collen said: “I am glad that Patrik has agreed to become ThromboGenics’s new CEO. His significant international management experience and his contribution to the company’s success over the last 18 months gives me great confidence that ThromboGenics will continue to prosper under his leadership.”